Stifel analyst Benjamin J. Burnett reiterated a Buy rating on Repare Therapeutics (NASDAQ: RPTX), following the company's recent AACR presentations ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE